Strong consumer spending, historically low unemployment and an easing of trade tensions with China initially fueled optimism early in the year for a 2020 bull market. But as the coronavirus pandemic has upended the global economy, uncertainty and disruption have replaced that once sunny outlook, and the life sciences ecosystem … … READ MORE >
Life sciences
Coronavirus disrupts the pipeline for new drugs and medical devices
On Tuesday, a day before the World Health Organization declared the coronavirus outbreak a pandemic, the Food and Drug Administration announced that it was postponing foreign inspections through April. … READ MORE >
Coronavirus and the rise of virtual health visits
The human toll of the coronavirus only continues to mount: Confirmed cases have topped 118,000, deaths have surpassed 4,000 and Italy has quarantined 16 million people. It has led employers around the globe to encourage employees to work from home or take unpaid leaves of absence. In Seattle, the epicenter … … READ MORE >
Shadow IT risk is growing as health care industry consolidates
As health care systems continue to consolidate, they must be aware of the information technology risks lurking in the shadows. … READ MORE >
Coronavirus reveals vulnerability in the life science supply chain
There is growing concern on how the coronavirus outbreak could affect the life science industry, especially the availability and quality of drugs and medical equipment. … READ MORE >
Advances in gene sequencing accelerate the response to coronavirus outbreak
Advances in analysis technology and gene sequencing have allowed for the genome of the coronavirus to be sequenced in less than a month after the first case of the virus was reported. … READ MORE >
Want a fuller picture of biotech’s promise? Look beyond the public markets
The biotech ecosystem and the capital markets in which it operates are complex; viewing this sector through the lens of the public markets doesn’t provide a complete picture of its promise to investors. … READ MORE >
Biotech needs cash in hesitant market
Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. … READ MORE >
Better data use has pros and cons for life sciences
The volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer genetic testing. Life science companies should consider how best to leverage this … … READ MORE >